Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Optimizing Genipin concentration for corneal collagen cross-linking: an ex-vivo model

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Cornea IV

Venue: Poster Village: Pod 3

First Author: : L.Bataille SPAIN

Co Author(s): :    A. Gharaibeh   V. Saez   N. Garcia   J. Alio     

Abstract Details

Purpose:

To optimize the crosslinking effect caused by Genipin at different concentrations, duration of treatment and delivery methods as a pharmacological substance for corneal collagen crosslinking (CXL) with the purpose of approving its clinical human application.

Setting:

Vissum Alicante, Spain

Methods:

100 corneas treated with different Genipin concentrations (0.1%, 0.5% and 1%) and treatment durations (15 minutes, 30 minutes, 40 minutes, 1 hour, 2 hours and 8 hours) through different methods of delivery (soaking or topical drops of 140 µl) were compared to 10 controls corneas treated with Riboflavin and UV. Histology exam, enzymatic digestion with collagenase and Thermal Differential Scanning Calorimetry (DSC) were performed on the different samples.

Results:

Corneas soaked 15 minutes in 0.5% Genipin (0.5G) are less crosslinked than control (4.7% and 5.6% respectively). Higher soaking time did not increase the crosslinking effect. Topical application of 0.5G every hour for 2 hours showed 7% crosslinking effect. Drops of 0.5G applied for 30 minutes, 1 and 2 hours showed lower enzymatic degradation compared to control (54 ± 6%, 40 ± 7%, 39 ± 9% and 74% respectively). Drops of 0.5G applied during 1, 2 and 8 hours showed higher thermal denaturation resistance than control (64.9 ± 0.3, 64.7 ± 0.0, 67.3 ± 0.9 and 64.6 ± 0.5 respectively).

Conclusions:

This experimental study demonstrates that 140 µl drops of Genipin 0.5% applied hourly for 2 hours is an efficient CXL treatment. Further tests to optimize the concentration of Genipin, the duration of treatment and the penetration in the cornea will be carried out before the application in humans.

Financial Disclosure:

NONE

Back to previous